Methamphetamine associated psychosis has increased globally because of the increased usage of the substance. The use of risperidone is noted to reduce the cravings of methamphetamine in patients who have methamphetamine use disorder. This becomes relevant because the number of patients who are being treated with MAP tends to have high relapse rates. MAP is being treated with different antipsychotics and the treatment protocol is made usually for alleviating the symptoms, a formal treatment regimen for patients with MAP is yet to be developed (Chiang et al 2018; Srisurapanont 2021; Edwards and Mooney 2014)

The purpose of this review is to highlight the use of risperidone in reducing the cravings of methamphetamine in patients who have methamphetamine use disorder

PubMed, SCOPUS and Web of Science literature databases were screened and filtered.With established Inclusion and exclusion criteria, obtained a total of 15578 hits which was refined to 133articles. A total of 10papers were reviewed in detail

Multiple clinical trials have shown that risperidone was effective in lowering drug cravings in methamphetamine use disorder. Along with the effects on craving, risperidone has also been studied for its effect on positive symptoms in patients with MAP (Samei 2016). Risperidone was noted to be effective in reducing positive symptoms.

Risperidone can be effectively used in the acute setting for psychosis and future cravings in the patients. Considering the limited clinical trials and research on risperidone and the cravings of methamphetamine use disorder, studies are needed with longer follow-ups and more samples in the future.

No significant relationships.

Coronaviruses traditionally are considered to cause pulmonary diseases, often accompanied by gastrointestinal symptoms. Since the COVID-19 pandemic start in early 2020, there have been reports of a high prevalence of neuropsychiatric symptoms. Recent data show significant rates of neuropsychiatric diagnosis over the subsequent 6 months post-infection. Some of the data suggest the COVID-19 as a cause of new-onset psychotic symptoms in patients with no psychiatric history. Delusions, hallucinations, disorganized thoughts, and confusion were the most frequently reported psychotic features which low doses of antipsychotics seem to be helpful.

Brief literature review about the relationship between COVID-19 and new-onset psychotic symptomatology.

Non-systematic review through PubMed research using the terms “COVID-19”, “SARS-CoV-2”, “pandemics”, “psychotic symptoms” and “psychosis”.

The severity of the infection, especially in those with the need for hospitalization/intensive care, seems to have a clear effect on the gravity of subsequent neuropsychiatric symptoms, namely psychosis. Viral invasion of the central neural system, hypercoagulable states, and neuroinflammation are potential associated mechanisms. It’s important to consider the effect of therapies that may have the potential to cause psychosis (eg steroids). According to recent literature, around 0.9-4% of people exposed to the COVID-19 virus develop psychotic episodes, which is much higher than the incidence in the general population.

Post-COVID-19 related psychosis has been reported in different nations. The pathophysiology is yet not clear, although the hyperinflammatory response has been suggested as the main mechanism for the neuropsychiatric manifestations. Given the high number of case reports with similar presentations, it’s important to proceed with more investigations.

No significant relationships.

Several risk factors make older adults more prone to psychosis. The persistent growth in the elderly population makes important the necessity of accurate diagnosis of psychosis, since this population has special features especially regarding to the pharmacotherapy and side effects.

To review the medical literature related to late-life psychosis.

Medline search and ulterior review of the related literature.

Reinhard et al. [1] highlight the fact that up to 60% of patients with late onset psychosis have a secondary psychosis, including: metabolic (electrolite abnormalities, vitamines defficiency…); infections (meningitides, encephalitides…); neurological (dementia, epilepsy…); endocrine (hypoglycemia…); and intoxication. Colijn et al. [2] describe the epidemiological and clinical features of the following disorders: schizophrenia (0.3% lifetime prevalence > 65 years); delusional disorder (0.18% lifetime prevalence); psychotic depression (0.35% lifetime prevalence); schizoaffective disorder (0.32% lifetime prevalence); Alzheimer disease (41.1% prevalence of psychotic symptoms); Parkinson's disease (43% prevalence of psychotic symptoms); Parkinson's disease dementia (89% prevalence of visual hallucinations); Lewy body dementia (up to 78% prevalence of hallucinations) and vascular dementia (variable estimates of psychotic symptoms). Recommendations for treatment include risperidone, olanzapine, quetiapine, aripiprazole, clozapine, donepezil and rivastigmine.

Differential diagnosis is tremendously important in elderly people, as late-life psychosis can be a manifestation of organic disturbances. Mental disorders such as schizophrenia or psychotic depression may have different manifestations in comparison with early onset psychosis.

The authors have not supplied their declaration of competing interest.